Analysis
Tiny Health, an Austin, Texas-based microbiome intelligence company, raised $33 million in a Series B round led by B Capital, according to The SaaS News, bringing its total funding to $46 million. The round also included Alumni Ventures, Gaingels and Spero Ventures.
What Tiny Health Actually Sells
Tiny Health sells at-home microbiome tests for babies, children and adults, with memberships and coaching that interpret results, plus a B2B platform, Powered by Tiny, for healthcare and precision health organizations. It started in early-life gut health, but the company says adult testing has now surpassed pediatric testing in volume. That consumer-health-plus-interpretation model puts it in similar territory to Viome, which has built a broader at-home biomarker-testing business spanning gut, oral and blood panels, though Tiny Health, which began with infant and maternal gut testing, now positions itself across the full lifespan, from early-life health to longevity and healthy aging.
βIt started in early-life gut health, but the company says adult testing has now surpassed pediatric testing in volume.β
Numbers In Context
$46 million in total funding for a consumer health-testing startup is meaningful but not enormous next to venture-backed diagnostics peers that have raised hundreds of millions -- a round size that suggests investors see a real but still early-stage business, for a company that says its platform already serves nearly 200,000 customers and more than 6,000 healthcare practitioners and is still building out its clinical evidence base.
The Competitive Landscape
B Capital's existing portfolio -- which includes health-adjacent bets like Precision Neuroscience and Flourish Health -- suggests the firm is building a broader healthcare thesis that Tiny Health fits into, rather than making an isolated bet on microbiome testing specifically.
The Harder Question
Tiny Health says it has published four scientific papers, including a 2025 randomized controlled trial in Pediatric Allergy and Immunology that found targeted microbiome interventions reduced infants' odds of developing eczema by 83%. But the company itself acknowledges there is no single universal definition of a healthy microbiome for older children and adults, and that evidence gap matters more than the funding size, since it determines how far Tiny Health's recommendations can be validated beyond early-life use cases. That gap between what the test measures and what it can confidently tell a parent to do is the harder problem than customer acquisition, and it is the question any serious diligence on this round should start with rather than ending on.